Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 1.33 | uM | 5904.092 | 0.6943 | 0.3294 | 0.8933 | |
| BT-20 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 6.67 | uM | 5904.092 | 0.5997 | 0.1284 | 0.8933 | |
| BT-20 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 33.3 | uM | 5904.092 | 0.4437 | -0.1948 | 0.8933 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 5905.091 | 0.9645 | 0.9217 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 5905.091 | 0.9737 | 0.9420 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 5905.091 | 0.9706 | 0.9350 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 5905.091 | 0.9807 | 0.9574 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 5905.091 | 0.9593 | 0.9101 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 5905.091 | 0.9793 | 0.9544 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 5905.091 | 0.9705 | 0.9348 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 5905.091 | 0.7001 | 0.3485 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 5905.091 | 0.3706 | -0.3325 | 0.9045 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 5906.091 | 1.0380 | 1.1204 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 5906.091 | 1.1081 | 1.3489 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 5906.091 | 0.9749 | 0.9220 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 5906.091 | 1.0258 | 1.0814 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 5906.091 | 1.0220 | 1.0693 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 5906.091 | 0.9790 | 0.9346 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 5906.091 | 0.9844 | 0.9513 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 5906.091 | 0.7443 | 0.2594 | 0.6385 | |
| BT-474 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 5906.091 | 0.4700 | -0.3869 | 0.6385 | |
| BT-483 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 5908.091 | 0.9420 | 0.7791 | 0.5109 | |
| BT-483 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 5908.091 | 0.9436 | 0.7851 | 0.5109 | |
| BT-483 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 5908.091 | 0.9262 | 0.7212 | 0.5109 | |
| BT-483 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 5908.091 | 0.9001 | 0.6278 | 0.5109 |